The researchers, led by Mark Davis, PhD, the director of Stanford Institute for Immunity, Transplantation and Infection in Palo Alto, Calif., found that vaccination with Pfizer’s two-dose series among those who have never had COVID-19 “induced robust CD4+ and CD8+ T-cell responses to the virus’ spike protein.”
The results are published in Immunity.
Those who had a past COVID-19 infection before being vaccinated with the Pfizer shots “produced spike-specific CD8+ T cells at considerably lower levels — and with less functionality — than people who were never infected. This immunity status “substantially” decreased among a third group of study participants who were never vaccinated.
“This dysfunction persists for a year or more after the active phase of infection, suggesting lasting damage, despite the absence or near absence of the relevant virus,” the researchers said in Immunity. “In this context, it may be that these attenuated CD8+ T cell responses contribute to long COVID, perhaps rendering patients unable to respond robustly to subsequent infections by SARS-CoV-2 variants or other pathogens.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
